Genetic Prioritization of Plasma Proteins Across Dementia Subtypes: A Proteome-Wide Mendelian Randomization and Bayesian Colocalization Analysis

Dementia is clinically and biologically heterogeneous, and genetically supported plasma protein associations across dementia subtypes remain incompletely characterized. We aimed to genetically prioritize plasma proteins associated with overall dementia and major dementia subtypes using proteome-wide Mendelian randomization (MR) and Bayesian colocalization. We used the UK Biobank Pharma Proteomics Project (UKB-PPP) as a harmonized source of cis-protein quantitative trait loci (cis-pQTLs) for 2,941 Olink-measured plasma analytes. The European-ancestry discovery cis-pQTL analysis included up to 34,557 participants, whereas 54,219 participants were profiled in the overall UKB-PPP. Outcomes included FinnGen R10 genome-wide association studies (GWAS) for dementia, Alzheimer’s dementia, vascular dementia, frontotemporal dementia, and unspecified dementia, plus a European GWAS for dementia with Lewy bodies. At the nominal threshold of P < 0.05, 134, 132, 102, 78, 101, and 112 exploratory protein–outcome signals were observed for dementia, Alzheimer’s dementia, vascular dementia, frontotemporal dementia, dementia with Lewy bodies, and unspecified dementia, respectively; 23 associations remained significant after outcome-specific Benjamini–Hochberg false discovery rate (FDR) correction. Key FDR-significant proteins included APOE, NECTIN2, PVR, SERPINF2, GRN, TREM2, and ATXN2L. The strongest risk and protective associations were NECTIN2 with Alzheimer’s dementia (odds ratio [OR] = 2.650, 95% confidence interval [CI]: 1.875–3.744, FDR-adjusted P = 1.58 × 10 − 5 ) and ATXN2L with dementia (OR = 0.408, 95% CI: 0.255–0.654, FDR-adjusted P = 0.0370), respectively. Strong colocalization support was observed for selected SERPINF2 and TREM2 associations. These findings genetically prioritize several plasma proteins as candidate biomarkers and potential therapeutic targets across dementia subtypes, but do not establish that circulating protein abundance directly mediates dementia risk.

Authors

Institutions

Publication Details

Journal
Cellular and Molecular Neurobiology
Published
2026-09-07
DOI
https://doi.org/10.1007/s10571-026-01819-2
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Genetic Prioritization of Plasma Proteins Across Dementia Subtypes: A Proteome-Wide Mendelian Randomization and Bayesian Colocalization Analysis

Jiaxi Li, Xinyang Yan, Jinning Song, Longxiao Zhang
Cellular and Molecular Neurobiology
Alzheimer's disease research and treatments
article

Genetic Prioritization of Plasma Proteins Across Dementia Subtypes: A Proteome-Wide Mendelian Randomization and Bayesian Colocalization Analysis

Jiaxi Li, Xinyang Yan, Jinning Song, Longxiao Zhang
article en

Abstract

Dementia is clinically and biologically heterogeneous, and genetically supported plasma protein associations across dementia subtypes remain incompletely characterized. We aimed to genetically prioritize plasma proteins associated with overall dementia and major dementia subtypes using proteome-wide Mendelian randomization (MR) and Bayesian colocalization. We used the UK Biobank Pharma Proteomics Project (UKB-PPP) as a harmonized source of cis-protein quantitative trait loci (cis-pQTLs) for 2,941 Olink-measured plasma analytes. The European-ancestry discovery cis-pQTL analysis included up to 34,557 participants, whereas 54,219 participants were profiled in the overall UKB-PPP. Outcomes included FinnGen R10 genome-wide association studies (GWAS) for dementia, Alzheimer’s dementia, vascular dementia, frontotemporal dementia, and unspecified dementia, plus a European GWAS for dementia with Lewy bodies. At the nominal threshold of P < 0.05, 134, 132, 102, 78, 101, and 112 exploratory protein–outcome signals were observed for dementia, Alzheimer’s dementia, vascular dementia, frontotemporal dementia, dementia with Lewy bodies, and unspecified dementia, respectively; 23 associations remained significant after outcome-specific Benjamini–Hochberg false discovery rate (FDR) correction. Key FDR-significant proteins included APOE, NECTIN2, PVR, SERPINF2, GRN, TREM2, and ATXN2L. The strongest risk and protective associations were NECTIN2 with Alzheimer’s dementia (odds ratio [OR] = 2.650, 95% confidence interval [CI]: 1.875–3.744, FDR-adjusted P = 1.58 × 10 − 5 ) and ATXN2L with dementia (OR = 0.408, 95% CI: 0.255–0.654, FDR-adjusted P = 0.0370), respectively. Strong colocalization support was observed for selected SERPINF2 and TREM2 associations. These findings genetically prioritize several plasma proteins as candidate biomarkers and potential therapeutic targets across dementia subtypes, but do not establish that circulating protein abundance directly mediates dementia risk.

Cellular and Molecular Neurobiology
Precision for Medicine (United States) (US), First Affiliated Hospital of Xi'an Jiaotong University (CN)
National Natural Science Foundation of China
Openalex Percentile: Top 11%
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.